Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg Ahmedabad, India, 11 April, 2025 Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari® (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ® Tablets, 6 mg, 18 mg, 30 mg, and 36 mg). Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Jaythari® (Deflazacort) will be produced at Doppel Farmaceutici S.r.l., Italy facility. The group now has 424 approvals and has so far filed 492* ANDAs since the commencement of the filing process in FY 2003-04. (*As on 31st March, 2025.)

The release as fetched from its publisher. zyduslife.com ↗